description
Powered by Eupheria Biotech
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
GCAACCACAAGTCCAATGTGATCAGGAAGAAACAGGTCCACCTCGAATTGGCTGTTACCATATCTCAACAGAAAACACGGAGAATTCGAAATTCGACGGGATTAAAGGACGCGTGAAAGGTTTGAGAGAAGAGAGATGCCGCTATTGAATCTGCTGGAGTTTTACATCCCAAGATGAAGACAGCATTCAGAATTGATGTGATTTCCTTGAATCGTGGCTTAGGAAATGTGGACACTTAAAACTCTCACTTGAAATTGGGCACAGGTTTGATGTAGAGATAAGGACGGGGTGCGGAATGGAGACCCATTTTGTCATTGATTCATCTGACCGATAAGGCCATAGTGCAGTTAGGTGATATTCGAAAGCTTCTTTGATGCTCTTTATGTATATGTTGGAAGGAACTACCAGGCGTTG
Ensembl | mouse accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Quality Level
Gene Information
mouse ... CD24A(12484), Cd24a(12484)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
存储类别
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.
Darren R Bisset et al.
Human molecular genetics, 24(17), 4971-4983 (2015-06-18)
RNA interference (RNAi) offers a promising therapeutic approach for dominant genetic disorders that involve gain-of-function mechanisms. One candidate disease for RNAi therapy application is myotonic dystrophy type 1 (DM1), which results from toxicity of a mutant mRNA. DM1 is caused
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持